ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-4-78-74-44-38
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions
What is Erytech Pharma's stock symbol?
Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."
What is the consensus analysts' recommendation for Erytech Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.
Has Erytech Pharma been receiving favorable news coverage?
Headlines about ERYP stock have trended positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Erytech Pharma earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Erytech Pharma's key competitors?
Some companies that are related to Erytech Pharma include Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Scholar Rock (SRRK), PDL BioPharma (PDLI), Translate Bio (TBIO), Avrobio (AVRO), Replimune Group (REPL), Gritstone Oncology (GRTS), Solid Biosciences (SLDB), Adaptimmune Therapeutics (ADAP), Adverum Biotechnologies (ADVM), Agenus (AGEN) and CASI Pharmaceuticals (CASI).
What other stocks do shareholders of Erytech Pharma own?
Who are Erytech Pharma's key executives?
Erytech Pharma's management team includes the folowing people:
- Mr. Gil Beyen, Chairman & CEO (Age 57)
- Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
- Mr. Eric Soyer, CFO & COO (Age 53)
- Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
- Naomi Eichenbaum, Director Investor Relations
When did Erytech Pharma IPO?
(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.
Who are Erytech Pharma's major shareholders?
Erytech Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.13%).
Which institutional investors are selling Erytech Pharma stock?
ERYP stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.
How do I buy shares of Erytech Pharma?
Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Erytech Pharma's stock price today?
One share of ERYP stock can currently be purchased for approximately $8.47.
How big of a company is Erytech Pharma?
Erytech Pharma has a market capitalization of $151.87 million. The company earns $-37,890,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.
What is Erytech Pharma's official website?
How can I contact Erytech Pharma?
Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]
MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
